Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Valuable research insights to steer pharma’s HCP engagement impact

By Michelle Kelly

- PMLiVE

Committing to diversity: the key to pharmaceutical supply chain resilience

By Carolyn Riegel

- PMLiVE

How brands can rise to meet consumers’ high self-care expectations

With ‘The Great Deceleration’ – a move towards slow living, and a focus on improving mental wellbeing being two predicted trends this year, does this open the door to a...

Fox&Cat

- PMLiVE

Novo Nordisk and Neomorph enter molecular glue degrader partnership worth over $1.4bn

The companies will work on therapies for cardiometabolic and rare diseases

- PMLiVE

AstraZeneca’s Voydeya receives CHMP recommendation for rare blood disease PNH

Up to 20% of PNH patients treated with a C5 inhibitor experience clinically significant extravascular haemolysis

- PMLiVE

Novartis and Genentech’s Xolair shown to significantly reduce allergic reactions to food

Food-related anaphylaxis results in 30,000 emergency room visits in the US each year

- PMLiVE

Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

The blood cancer affects approximately 160,000 people worldwide

- PMLiVE

Researchers develop screening tool to investigate mechanisms behind multiple diseases

The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

- PMLiVE

Landmark project boosts sex and gender equity in UK medical research

Major funders are committing to only approving research projects that treat men and women fairly

Photo of Jon in Cuttsy+Cuttsy branded shapes

Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director

Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.

Cuttsy + Cuttsy

- PMLiVE

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

Biogen Idec building

Biogen’s Qalsody recommended by CHMP to treat rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all ALS cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links